UNSPSC 51372104: Dihydrocodeine

This classification denotes an opioid receptor agonist and opioid with the molecular formula C18H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N9I9HDB855, chemically known as 7, 8-dihydrocodeine but generally known as dihydrocodeine, which bears US NIH Compound Identifier 3063. European Medicines Agency schedules Dihydrocodeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07138MIG. The term DIHYDROCODEINE is an International Non-Proprietary Name.

UNSPSC 51372104 Dihydrocodeine, a Commodity code, covers pharmaceutical supplies and controlled substances that state and local governments procure for public health, emergency response, and community health programs. The recent solicitations under this code show state and local buyers acquiring naloxone, generic multi-source pharmaceuticals, and OTC products—not dihydrocodeine specifically—through competitive bidding and cooperative purchasing frameworks. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating state and local members). The work involves establishing supply contracts for pharmaceutical manufacturers and authorized wholesalers to deliver products through established distribution channels, with vendors responsible for compliance with cGMP, FDA requirements, Drug Supply Chain Security Act certification, and state-mandated insurance and employment verification.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the response deadline was July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capability information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, with no formal award timeline specified. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities; the proposal deadline was March 26, 2026, with awards effective July 1, 2026, and price competitiveness weighted at 75 percent of evaluation.